Security key
12674W109
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 72,777,604
- Total 13F value
- $110,698,611
- Share change
- +36,485,527
- Put/Call ratio
- 22%
- SEC-reported price per share
- $1.52
- Number of holders
- 85
- Value change
- +$55,724,802
- Number of buys
- 50
- Number of sells
- 58
- Shares outstanding
- 212,877,018
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
85
Top holders
10
CABA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Cabaletta Bio, Inc. SEC filings
Cabaletta Bio, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 12674W109
Recent filing periods:
Ownership snapshot
Top reported holders of CABA - Cabaletta Bio, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
Lead comparable stake: 10%
13D/G row: Bain Capital Life Sciences Opportunities III, LP
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Opportunities III, LP leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Bain Capital Life Sciences Opportunities III, LP's linked filing trail.
Comparable ownership
Top 5
Bain Capital Life Sciences Opport...
10%
Adage Capital Management, L.P.
10%
VANGUARD GROUP INC
3.8%
Nichtberger Steven
3.3%
BlackRock, Inc.
1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Opportunities III, LP |
13D/G
|
10%
|
$15,483,400
9,677,125 shares
|
$0 | 30 Jun 2025 |
| Adage Capital Management, L.P. |
13D/G
|
10%
|
$14,404,128
9,002,580 shares
|
$0 | 30 Jun 2025 |
| VANGUARD GROUP INC |
13D/G
13F
The Vanguard Group · Company
|
3.8%
|
$5,245,105
3,450,727 shares
|
$0 | 30 Jun 2025 |
| Nichtberger Steven |
13D/G
|
3.3%
|
$4,855,198
3,034,499 shares
|
$0 | 30 Jun 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
1%
from 13D/G
|
$4,781,223
3,452,147 shares
|
— | 31 Mar 2025 |
| T. Rowe Price Investment Management, Inc. |
13F
Company
|
1.9%
|
$5,499,000
3,970,026 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
85
Shares
72,777,604
Rows available
85
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
91
Q2 2025 holders
85
Holder diff
-6
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend